LFCR · XBRL financial data

Lifecore Biomedical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LFCR's year ends in late December)

In thousands of dollars	FY 2021May 30, 2021	FY 2022May 29, 2022	FY 2023May 28, 2023	FY 2024May 26, 2024	FY 2025May 25, 2025	FY 2025Dec 31, 2025
Cost of goods and services sold	462,687	135,416	75,284	86,411	88,569	—
Gross profit	81,474	50,370	27,985	41,850	40,298	—
Research and development	10,222	7,841	8,736	8,575	8,258	—
Selling, general and administrative	65,364	46,127	38,969	40,463	44,046	—
Total operating expenses	94,970	109,018	49,781	50,694	—	—
Operating income (loss)	(13,496)	(58,648)	(21,796)	(8,844)	(17,245)	—
Interest income	48	81	68	58	333	—
Interest expense	8,933	17,357	17,649	18,148	21,835	—
Other income (expense)	(11,689)	641	(1,159)	(3,052)	(3)	—
Income tax expense (benefit)	(7,801)	(5,945)	308	183	43	—
Net income (loss)	(32,665)	(114,679)	(99,563)	12,013	(38,717)	—
Earnings per share, basic USD per share	(1.12)	(3.90)	(3.32)	0.40	(1.27)	—
Earnings per share, diluted USD per share	(1.12)	(3.90)	(3.32)	0.32	(1.27)	—
Weighted average shares, basic thousands of shares	29,294	29,466	29,958	30,474	34,819	—
Weighted average shares, diluted thousands of shares	29,294	29,466	29,958	36,658	34,819	—

Fiscal years (LFCR's year ends in late December)

In thousands of dollars	FY 2021May 30, 2021	FY 2022May 29, 2022	FY 2023May 28, 2023	FY 2024May 26, 2024	FY 2025May 25, 2025	FY 2025Dec 31, 2025
Cash and cash equivalents	1,295	1,643	19,091	8,462	8,265	17,469
Accounts receivable	70,013	48,172	29,024	31,153	—	—
Inventory	69,663	66,845	40,841	39,979	32,291	29,085
Prepaid and other current assets	7,350	7,052	4,919	1,439	1,454	1,921
Total current assets	148,321	123,712	93,875	81,033	85,677	82,292
Property and equipment, net	179,559	118,531	134,390	148,598	129,006	127,304
Right-of-use asset	20,827	8,580	4,282	2,442	—	—
Goodwill	69,386	13,881	13,881	13,881	13,881	13,881
Total assets	502,924	277,806	253,545	253,960	239,342	232,177
Accounts payable	47,569	15,802	22,097	16,334	8,220	5,839
Accrued liabilities	—	—	—	22,538	21,958	17,734
Current portion of long-term debt	0	98,178	580	773	3,437	954
Total current liabilities	101,888	176,810	39,289	38,872	30,178	23,573
Long-term debt	164,902	0	84,256	100,819	—	—
Lease liability, non-current	20,305	9,971	6,495	1,729	1,343	1,120
Total liabilities	300,140	187,109	218,457	200,058	191,909	198,117
Retained earnings (accumulated deficit)	38,580	(76,099)	(178,536)	(166,523)	(205,240)	(223,201)
Total stockholders' equity	202,784	90,697	(4,230)	11,315	1,336	(14,202)
Total liabilities and equity	502,924	277,806	253,545	253,960	239,342	232,177
Common shares outstanding (cover page) thousands of shares	29,457	29,596	30,547	30,898	37,408	37,477

Fiscal years (LFCR's year ends in late December)

In thousands of dollars	FY 2021May 30, 2021	FY 2022May 29, 2022	FY 2023May 28, 2023	FY 2024May 26, 2024	FY 2025May 25, 2025	FY 2025Dec 31, 2025
Net income (loss)	(32,665)	(114,679)	(99,563)	12,013	(38,717)	—
Stock-based compensation	3,360	2,608	3,612	6,201	10,158	—
Depreciation and amortization	19,867	17,884	13,285	8,859	8,027	—
Net cash from operating activities	15,017	(24,399)	(17,441)	(217)	(206)	—
Purchases of property and equipment	23,769	26,226	—	18,395	13,415	—
Net cash from investing activities	(10,856)	81,768	(4,811)	(17,921)	(6,415)	—
Proceeds from issuing common stock	0	0	4,822	0	23,850	—
Proceeds from long-term debt	170,000	20,000	150,000	—	—	—
Repayments of long-term debt	114,130	86,411	123,690	0	—	—
Net cash from financing activities	(3,419)	(57,021)	39,700	7,509	6,424	—
Net change in cash	742	348	17,448	(10,629)	(197)	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lifecore Biomedical	23,035	25,322	6,946*	37.9M	—	Q3 FY26 10-QSep 30, 2026
Precigen	16,329	54,978	(17,809)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.